Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Marc

Showing results (111-120 of 124) with videos related to

Pageof 13
Sort By:
Clinical and Vaccine Immunology : CVI|July 15, 2011
Meningococcal group C and w135 immunological hyporesponsiveness in african toddlersHelen Findlow, Samba Sow, Ray Borrow, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2015
Public Health Impact After the Introduction of PsA-TT: The First 4 YearsFabien V K Diomandé, Mamoudou H Djingarey, Doumagoum M Daugla, et al.
La Revue De Medecine Interne|June 19, 2012
[Crushing drugs in geriatric units: an "handicraft" practice with frequent errors which imposed recommendations]M Caussin, W Mourier, S Philippe, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 24, 2007
Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemiaDaniella M B Kerbauy, Theodore A Gooley, George E Sale, et al.
Vaccine|August 18, 2012
Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trialSiddhivinayak Hirve, Ashish Bavdekar, Anand Pandit, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 23, 2012
Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunityPaul A Kristiansen, Fabien Diomandé, Absatou Ky Ba, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2015
Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of AgeMilagritos D Tapia, Helen Findlow, Olubukola T Idoko, et al.
Vaccine|September 18, 2025
Immunogenicity and safety of a meningococcal a conjugate vaccine administered with routine EPI vaccines in African infants and toddlersAbraham Hodgson, Fadima Cheick Haidara, Samba O Sow, et al.
The New England Journal of Medicine|June 17, 2011
Immunogenicity and safety of a meningococcal A conjugate vaccine in AfricansSamba O Sow, Brown J Okoko, Aldiouma Diallo, et al.
Journal of Clinical Medicine|October 14, 2022
Addressing Drug Resistance in Cancer: A Team Medicine ApproachPrakash Kulkarni, Atish Mohanty, Supriyo Bhattacharya, et al.
Pageof 13

Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
Clinical and Vaccine Immunology : CVI|July 15, 2011
Meningococcal group C and w135 immunological hyporesponsiveness in african toddlersHelen Findlow, Samba Sow, Ray Borrow, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2015
Public Health Impact After the Introduction of PsA-TT: The First 4 YearsFabien V K Diomandé, Mamoudou H Djingarey, Doumagoum M Daugla, et al.
La Revue De Medecine Interne|June 19, 2012
[Crushing drugs in geriatric units: an "handicraft" practice with frequent errors which imposed recommendations]M Caussin, W Mourier, S Philippe, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 24, 2007
Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemiaDaniella M B Kerbauy, Theodore A Gooley, George E Sale, et al.
Vaccine|August 18, 2012
Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trialSiddhivinayak Hirve, Ashish Bavdekar, Anand Pandit, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 23, 2012
Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunityPaul A Kristiansen, Fabien Diomandé, Absatou Ky Ba, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2015
Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of AgeMilagritos D Tapia, Helen Findlow, Olubukola T Idoko, et al.
Vaccine|September 18, 2025
Immunogenicity and safety of a meningococcal a conjugate vaccine administered with routine EPI vaccines in African infants and toddlersAbraham Hodgson, Fadima Cheick Haidara, Samba O Sow, et al.
The New England Journal of Medicine|June 17, 2011
Immunogenicity and safety of a meningococcal A conjugate vaccine in AfricansSamba O Sow, Brown J Okoko, Aldiouma Diallo, et al.
Journal of Clinical Medicine|October 14, 2022
Addressing Drug Resistance in Cancer: A Team Medicine ApproachPrakash Kulkarni, Atish Mohanty, Supriyo Bhattacharya, et al.
Pageof 13